PHILADELPHIA, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that the full text of the Hemispherx presentation given at the National Press Club (NPC) Conference in Washington, DC, on January 30, 2014 is being posted on the corporate website ( www.hemispherx.net ). The NPC presentation followed the announcement of new clinical data at the American Society of Microbiology (ASM) Biodefense Conference in Washington, DC, on January 29, 2014. Brief summaries of the clinical results were thereafter published on February 10, 2014 in Drug Discovery News ( http://www.ddn-news.com/index.php?newsarticle=8120 ) entitled Hemispherx Biopharma reports progress toward a universal influenza vaccine to prevent pandemic threats and on January 30, 2014 in Science Business Tech News ( http://sciencebusiness.technewslit.com/?p=16676 ) entitled Early Trial Finds Vaccine Booster Covers Pandemic Flu Types.
This clinical effort is the culmination of several years of research including primate testing on the development of a broad spectrum, pandemic influenza vaccine, initiated at the Japanese National Institute of Infectious Diseases, Tokyo, Japan. The present clinical work is in collaboration with the University of Alabama Vaccine Research Clinic, Birmingham, Alabama. The present research is being conducted with FluMist®, a commercially available intranasal seasonal influenza vaccine, and the Company anticipates the extension of this clinical research with other promising seasonal influenza vaccines to determine the extent, if any, of cross-reactivity conveyed by co-administration of the selective TLR-3 activator, rintatolimod, which is an experimental immunotherapeutic.
About Hemispherx BiopharmaHemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutics Ampligen® and Alferon® LDO. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because both Ampligen® and Alferon® LDO are experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials. Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®), approved for sale in the U.S. and Argentina. The Company's Alferon N approval in Argentina includes the use of Alferon N Injection (under the brand name "Naturaferon") for use in any patients who fail or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection. The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net . About University of Alabama at Birmingham Medical Center Fellows and faculty actively participate in teaching and patient care at the three major hospitals within the University of Alabama at Birmingham Medical Center. Their strong clinical presence is evidenced by two separate consult services (one in the 1100 bed University Hospital which focuses on opportunistic infections in compromised hosts such as BM and solid organ transplant recipients, bone/joint and CNS infections in orthopedic, trauma and neurosurgical patients, and infections in neutropenic/cancer patients; another service combines HIV/AIDS consultation at University Hospital and general infectious diseases consultation at the VA Medical Center and the county hospital). ID faculty and fellows also provide care in a cross-section of ambulatory clinics which target general ID, HIV/AIDS, STD, tuberculosis and international travel.